Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04888468
Other study ID # PB01
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date November 5, 2019
Est. completion date September 1, 2021

Study information

Verified date May 2021
Source Chongqing Precision Biotech Co., Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase I clinical study to evaluate the safety and tolerability of pCAR-19B in patients with relapsed or refractory B-ALL, and to obtain the maximum tolerated dose of pCAR-19B and phase II Recommended dose.


Description:

This is a single-center, single-arm, open-label study. The study plans to set up 3 dose groups, adopting a dose-escalating 3+3 design, and plan to recruit about 9-18 subjects with relapsed or refractory B-ALL.pCAR-19B will be infused to the subject by intravenous infusion.


Recruitment information / eligibility

Status Completed
Enrollment 9
Est. completion date September 1, 2021
Est. primary completion date June 29, 2021
Accepts healthy volunteers No
Gender All
Age group 3 Years to 21 Years
Eligibility Inclusion Criteria: 1. Diagnosed with B-ALL,and meet one of the following conditions: 1. First-line or multiple-line salvage chemotherapy did not achieve complete remission; 2. Early relapse after complete remission (<12 months), or late relapse after complete remission (=12 months) and complete remission has not been achieved after 1 course of treatment; 3. Relapse after autologous or allogeneic hematopoietic stem cell transplantation; 2. Ph+ALL patients should also receive at least two TKI treatments; 3. For allogeneic hematopoietic stem cell transplant subjects, the following conditions must be met: 1. Allo-HSCT takes =6 months before pCAR-19B infusion; 2. No GVHD of grade 2 or above occurred within 2 weeks before PBMC collection; 4. Express CD19; 5. 3~21 years old, no gender limit; 6. The expected survival time is more than 12 weeks; 7. KPS>60; 8. No serious mental disorders; 9. The function of important organs is basically normal: 1. Heart function: echocardiography indicates that the cardiac ejection fraction is =50%, and the electrocardiogram has no obvious abnormalities; 2. Renal function: serum creatinine=2.0×ULN; 3. Liver function: ALT and AST =5×ULN; 4. Total bilirubin and alkaline phosphatase=3×ULN ; 5. Blood oxygen saturation>92%. 10. Have standards for apheresis or venous blood collection, and no other cell collection contraindications; 11. The patient himself or his guardian agrees to participate in the clinical trial and signs the ICF, indicating that he understands the purpose and procedures of the clinical trial and is willing to participate in the research. Exclusion Criteria: 1. With central nervous system disease at the time of screening; 2. Have received CAR-T therapy or other genetically modified cell therapy; 3. Participated in other clinical studies within 1 month before screening; 4. Have received the following anti-tumor treatments before screening: received chemotherapy, targeted therapy or other experimental drug treatments within 14 days or at least 5 half-lives (whichever is shorter); 5. Have received a live attenuated vaccine within 4 weeks before screening; 6. Cerebrovascular accident or seizure occurred within 6 months before signing the ICF; 7. Suffered from any of the following heart diseases: 1. NYHA stage III or IV congestive heart failure; 2. Myocardial infarction or CABG occurred =6 months before enrollment; 3. Clinically significant ventricular arrhythmia, or history of unexplained syncope (except for cases caused by vasovagal or dehydration); 4. History of severe non-ischemic cardiomyopathy. 8. Uncontrollable infection in the 2 weeks before screening; 9. Active autoimmune diseases; 10. Patients with malignant tumors other than acute lymphoblastic leukemia within 5 years before screening, except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and duct in situ after radical resection cancer; 11. HBsAg or HBcAb positive and HBV DNA is greater than the normal range; HCV antibody is positive and HCV RNA greater than the normal range; HIV antibody positive; syphilis positive; CMV DNA positive; 12. Women who are pregnant or breastfeeding, and male or female subjects who plan to have children within 1 year after receiving pCAR-19B cell reinfusion; 13. Other situations considered by the researcher to be unsuitable to participate in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
pCAR-19B cells
Drug: pCAR-19B cells; Administration method: intravenous infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.

Locations

Country Name City State
China Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Chongqing Precision Biotech Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Adverse events after pCAR-19B infusion [Safety and Tolerability] Therapy-related adverse events were recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0) 28 days
Primary Obtain the maximum tolerated dose of pCAR-19B cells[Safety and Tolerability] Dose-limiting toxicity after cell infusion 28 days
Secondary Objective response rate after pCAR-19B infusion [Effectiveness] Objective response rate includes CR, CRi 3 months
Secondary AUCS of pCAR-19B cells [Cell dynamics] AUCS is defined as the area under the curve in 28 days and 90 days 3 months
Secondary CMAX of pCAR-19B cells [Cell dynamics] CMAX is defined as the highest concentration of pCAR-19B cells expanded in peripheral blood 3 months
Secondary TMAX of pCAR-19B cells [Cell dynamics] TMAX is defined as the time to reach the highest concentration 3 months
Secondary Pharmacodynamics of pCAR-19B cells[Cell dynamics] Cytokines such as hs-CRP, IL-6 levels 3 months
Secondary Immunogenicity of pCAR-19B cells Anti-CAR antibody 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Recruiting NCT05772000 - Clinical Significance of Occult Central Nervous System Localization
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Active, not recruiting NCT03114865 - A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance Phase 1/Phase 2
Not yet recruiting NCT06308588 - Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Phase 2
Recruiting NCT05579132 - A Phase Ib/II Study of CN201 in Precursor B-cell Acute Lymphoblastic Leukemia Phase 1/Phase 2
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Terminated NCT02231853 - Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections Phase 1
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2
Recruiting NCT06195891 - Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome Phase 1
Withdrawn NCT02815059 - Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone Phase 1
Completed NCT00390793 - Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. Phase 2
Recruiting NCT05866887 - Insomnia Prevention in Children With Acute Lymphoblastic Leukemia N/A
Completed NCT00026780 - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Not yet recruiting NCT06350994 - Early Assessment of Cardiac Function After Treatment With CAR-T Cells
Withdrawn NCT04282174 - CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies Phase 2
Not yet recruiting NCT04488237 - Vitamin D and Methotrexate Adverse Effects
Completed NCT02544438 - Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Phase 1/Phase 2